Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field
ObjectiveThe study was designed to explore the evolution of non-small cell lung cancer (NSCLC) management in the last 20 years.MethodsThe top 100 most-cited papers on NSCLC treatment were retrieved from the Web of Science Core Collection database. R and VOSviewer were used to extract bibliographic i...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.939838/full |
| _version_ | 1798037243609219072 |
|---|---|
| author | Siyuan Chen Siyuan Chen Yu Qiao Juan Chen Yanan Li Yanan Li Jianlian Xie Pengfei Cui Pengfei Cui Ziwei Huang Ziwei Huang Di Huang Di Huang Yiming Gao Yiming Gao Yi Hu Zhefeng Liu |
| author_facet | Siyuan Chen Siyuan Chen Yu Qiao Juan Chen Yanan Li Yanan Li Jianlian Xie Pengfei Cui Pengfei Cui Ziwei Huang Ziwei Huang Di Huang Di Huang Yiming Gao Yiming Gao Yi Hu Zhefeng Liu |
| author_sort | Siyuan Chen |
| collection | DOAJ |
| description | ObjectiveThe study was designed to explore the evolution of non-small cell lung cancer (NSCLC) management in the last 20 years.MethodsThe top 100 most-cited papers on NSCLC treatment were retrieved from the Web of Science Core Collection database. R and VOSviewer were used to extract bibliographic information, including the year of publication, countries/regions, institutions, authors, journals, keywords, impact factor, and total citations. The topic and type of papers were checked independently by authors. Bibliometric analysis was conducted and visualized with R, CiteSpace, Excel and VOSviewer to identify output dynamics, research forces, topics, hotspots, and frontiers in the field.ResultsThe average citation of each retrieved top 100 most-cited NSCLC management papers was 1,725 (range: 615-7,340). Fifty-seven corresponding authors were from the United States. This country contributed the most papers (n=76), followed by Germany (n=34), France (n=33), and South Korea (n=32). The top contributors were Paz-Ares L. (n=12) and Reck M. (n=12). The Memorial Sloan Kettering Cancer Center published the largest number of papers (n=20). There were two significant citation paths, indicating publications in medicine/medical/clinical journals primarily cited journals in molecular/biology/genetics fields, partly cited health/nursing/medicine fields. Top-cited papers mainly came from the New England Journal of Medicine (n=33, citations=80,427), followed closely by the Journal of Clinical Oncology (n=28, citations=32,408). “Chemotherapy” (n=36) was the keyword with the greatest frequency of co-occurrence. “Open-label” was the keyword with the strongest burst strength (=4.01), followed by “nivolumab” (=3.85), “blockade” (=2.86), and “efficacy” (=2.85).ConclusionsThe United States as a nation and the Memorial Sloan Kettering Cancer Center as an institute contributed the most to this field. The New England Journal of Medicine is the most eye-catching journal. Hotspots of NSCLC management have almost undergone an evolution from chemotherapy and radiotherapy to targeted therapy to immunotherapy. Molecular/biological/genetic fields become the main research base for NSCLC treatment. Immunotherapy and combination therapy are research frontiers. |
| first_indexed | 2024-04-11T21:23:57Z |
| format | Article |
| id | doaj.art-650d61551cd04a50b9d004727e12a79a |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T21:23:57Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-650d61551cd04a50b9d004727e12a79a2022-12-22T04:02:29ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.939838939838Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the fieldSiyuan Chen0Siyuan Chen1Yu Qiao2Juan Chen3Yanan Li4Yanan Li5Jianlian Xie6Pengfei Cui7Pengfei Cui8Ziwei Huang9Ziwei Huang10Di Huang11Di Huang12Yiming Gao13Yiming Gao14Yi Hu15Zhefeng Liu16Department of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, ChinaSchool of Nursing, Yangzhou University, Yangzhou, ChinaDepartment of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaDepartment of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaDepartment of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaDepartment of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaDepartment of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaDepartment of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, ChinaObjectiveThe study was designed to explore the evolution of non-small cell lung cancer (NSCLC) management in the last 20 years.MethodsThe top 100 most-cited papers on NSCLC treatment were retrieved from the Web of Science Core Collection database. R and VOSviewer were used to extract bibliographic information, including the year of publication, countries/regions, institutions, authors, journals, keywords, impact factor, and total citations. The topic and type of papers were checked independently by authors. Bibliometric analysis was conducted and visualized with R, CiteSpace, Excel and VOSviewer to identify output dynamics, research forces, topics, hotspots, and frontiers in the field.ResultsThe average citation of each retrieved top 100 most-cited NSCLC management papers was 1,725 (range: 615-7,340). Fifty-seven corresponding authors were from the United States. This country contributed the most papers (n=76), followed by Germany (n=34), France (n=33), and South Korea (n=32). The top contributors were Paz-Ares L. (n=12) and Reck M. (n=12). The Memorial Sloan Kettering Cancer Center published the largest number of papers (n=20). There were two significant citation paths, indicating publications in medicine/medical/clinical journals primarily cited journals in molecular/biology/genetics fields, partly cited health/nursing/medicine fields. Top-cited papers mainly came from the New England Journal of Medicine (n=33, citations=80,427), followed closely by the Journal of Clinical Oncology (n=28, citations=32,408). “Chemotherapy” (n=36) was the keyword with the greatest frequency of co-occurrence. “Open-label” was the keyword with the strongest burst strength (=4.01), followed by “nivolumab” (=3.85), “blockade” (=2.86), and “efficacy” (=2.85).ConclusionsThe United States as a nation and the Memorial Sloan Kettering Cancer Center as an institute contributed the most to this field. The New England Journal of Medicine is the most eye-catching journal. Hotspots of NSCLC management have almost undergone an evolution from chemotherapy and radiotherapy to targeted therapy to immunotherapy. Molecular/biological/genetic fields become the main research base for NSCLC treatment. Immunotherapy and combination therapy are research frontiers.https://www.frontiersin.org/articles/10.3389/fonc.2022.939838/fullnon-small cell lung cancer (NSCLC)managementtreatmentbibliometricRVOSviewer |
| spellingShingle | Siyuan Chen Siyuan Chen Yu Qiao Juan Chen Yanan Li Yanan Li Jianlian Xie Pengfei Cui Pengfei Cui Ziwei Huang Ziwei Huang Di Huang Di Huang Yiming Gao Yiming Gao Yi Hu Zhefeng Liu Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field Frontiers in Oncology non-small cell lung cancer (NSCLC) management treatment bibliometric R VOSviewer |
| title | Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field |
| title_full | Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field |
| title_fullStr | Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field |
| title_full_unstemmed | Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field |
| title_short | Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field |
| title_sort | evolutions in the management of non small cell lung cancer a bibliometric study from the 100 most impactful articles in the field |
| topic | non-small cell lung cancer (NSCLC) management treatment bibliometric R VOSviewer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.939838/full |
| work_keys_str_mv | AT siyuanchen evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT siyuanchen evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT yuqiao evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT juanchen evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT yananli evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT yananli evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT jianlianxie evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT pengfeicui evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT pengfeicui evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT ziweihuang evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT ziweihuang evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT dihuang evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT dihuang evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT yiminggao evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT yiminggao evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT yihu evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield AT zhefengliu evolutionsinthemanagementofnonsmallcelllungcancerabibliometricstudyfromthe100mostimpactfularticlesinthefield |